Climb BioNASDAQ: CLYM

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Next earnings report:

15 May 2025

Last dividends:

N/A

Next dividends:

N/A
$201.67 M
-66%vs. 3y high
54%vs. sector
-vs. 3y high
-vs. sector
-66%vs. 3y high
37%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Thu, 21 Nov 2024 14:30:00 GMT
$3.00-$0.08(-2.60%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

Included in screeners

No data

CLYM Latest News

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
globenewswire.com12 November 2024 Sentiment: POSITIVE

Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D.

Climb Bio Appoints Douglas E. Williams, Ph.D.
globenewswire.com11 November 2024 Sentiment: POSITIVE

WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio's Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has held leadership roles in research and development, contributing significantly to the creation of drugs such as Leukine®, Enbrel®, Adcetris®, Tecfidera®, Alprolix®, Eloctate® and Spinraza®. As a CEO, he has successfully guided both private and public companies from development to commercialization and has overseen multiple successful mergers.

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
globenewswire.com15 October 2024 Sentiment: POSITIVE

Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025 Outlines Plans for Clinical Trial s in Systemic Lupus Erythematosus (SLE) and Immune Thrombocytopenia (ITP) with First Patients Dosed Targeted for 1H25 Cash runway through 2027 Expected to Enable Delivery of Key Value Inflection Points Virtual Investor Event to be Held at 12:00 p.m. ET Today WELLESLEY HILLS, Mass.

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
globenewswire.com11 October 2024 Sentiment: POSITIVE

WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024.

What type of business is Climb Bio?

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

What sector is Climb Bio in?

Climb Bio is in the Healthcare sector

What industry is Climb Bio in?

Climb Bio is in the Biotechnology industry

What country is Climb Bio from?

Climb Bio is headquartered in United States

What is Climb Bio website?

https://eliemtx.com

Is Climb Bio in the S&P 500?

No, Climb Bio is not included in the S&P 500 index

Is Climb Bio in the NASDAQ 100?

No, Climb Bio is not included in the NASDAQ 100 index

Is Climb Bio in the Dow Jones?

No, Climb Bio is not included in the Dow Jones index

When was Climb Bio the previous earnings report?

No data

When does Climb Bio earnings report?

The next expected earnings date for Climb Bio is 15 May 2025